“The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial”, J of Skin, vol. 6, no. 6, p. s77, Nov. 2022, doi: 10.25251/skin.6.supp.77.